C

Claritas Pharmaceuticals Inc
XTSX:CLAS

Watchlist Manager
Claritas Pharmaceuticals Inc
XTSX:CLAS
Watchlist
Price: 0.295 CAD Market Closed
Market Cap: 10.4m CAD

Relative Value

CLAS doesn't have a meaningful market cap.

There is not enough data to reliably calculate the relative value of CLAS.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

CLAS Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
2.6
vs History
vs Industry
Median 3Y
-1.6
Median 5Y
-1.6
Industry
21.4
vs History
vs Industry
Median 3Y
-8
Median 5Y
-8
Industry
16.4
vs History
vs Industry
Median 3Y
-12.2
Median 5Y
-12.2
Industry
22.8
vs History
vs Industry
Median 3Y
2.3
Median 5Y
2.3
Industry
2.2
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
2.9
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
5.5
vs History
vs Industry
Median 3Y
15.5
Median 5Y
15.4
Industry
13
vs History
vs Industry
Median 3Y
15.5
Median 5Y
15.4
Industry
16.5
vs History
vs Industry
Median 3Y
-8
Median 5Y
-8
Industry
15.6
vs History
vs Industry
Median 3Y
-8
Median 5Y
-8
Industry
18.7
vs History
vs Industry
Median 3Y
0.7
Median 5Y
0.7
Industry
1.9

Multiples Across Competitors

CLAS Competitors Multiples
Claritas Pharmaceuticals Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Claritas Pharmaceuticals Inc
XTSX:CLAS
10.4m CAD 0 -1.6 15.4 15.4
US
Eli Lilly and Co
NYSE:LLY
997.6B USD 16.9 54.7 36.4 39
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
494.8B USD 5.3 19.6 16.1 20.9
CH
Roche Holding AG
SIX:ROG
263.6B CHF 4.3 28 11.9 13.9
UK
AstraZeneca PLC
LSE:AZN
218.4B GBP 5.1 31.5 109 159.5
CH
Novartis AG
SIX:NOVN
214.5B CHF 4.8 18.8 11.9 15.4
US
Merck & Co Inc
NYSE:MRK
270.7B USD 4.2 14.2 10.1 12
DK
Novo Nordisk A/S
CSE:NOVO B
1.6T DKK 5.2 15.7 11 12.7
IE
Endo International PLC
LSE:0Y5F
213.9B USD 92.2 -73.2 338.7 849.2
US
Pfizer Inc
NYSE:PFE
146.1B USD 2.3 14.9 7.6 10.3
P/E Multiple
Earnings Growth PEG
US
C
Claritas Pharmaceuticals Inc
XTSX:CLAS
Average P/E: 24.7
Negative Multiple: -1.6
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
54.7
54%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.6
29%
0.7
CH
Roche Holding AG
SIX:ROG
28
29%
1
UK
AstraZeneca PLC
LSE:AZN
31.5
37%
0.9
CH
Novartis AG
SIX:NOVN
18.8
17%
1.1
US
Merck & Co Inc
NYSE:MRK
14.2
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
15.7
3%
5.2
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -73.2 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.9
27%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
C
Claritas Pharmaceuticals Inc
XTSX:CLAS
Average EV/EBITDA: 401.3
15.4
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
36.4
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.1
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.9
5%
2.4
UK
AstraZeneca PLC
LSE:AZN
109
10%
10.9
CH
Novartis AG
SIX:NOVN
11.9
6%
2
US
Merck & Co Inc
NYSE:MRK
10.1
6%
1.7
DK
Novo Nordisk A/S
CSE:NOVO B
11
1%
11
IE
E
Endo International PLC
LSE:0Y5F
338.7
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.6
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
C
Claritas Pharmaceuticals Inc
XTSX:CLAS
Average EV/EBIT: 1 713.7
15.4
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
39
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
20.9
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.9
6%
2.3
UK
AstraZeneca PLC
LSE:AZN
159.5
23%
6.9
CH
Novartis AG
SIX:NOVN
15.4
12%
1.3
US
Merck & Co Inc
NYSE:MRK
12
8%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
12.7
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
849.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.3
7%
1.5